| Literature DB >> 26355029 |
Piotr Trzonkowski1, Rosa Bacchetta2, Manuela Battaglia3, David Berglund4, Hermann Richard Bohnenkamp5, Anja ten Brinke6, Andrew Bushell7, Nathalie Cools8, Edward K Geissler9, Silvia Gregori10, S Marieke van Ham6, Catharien Hilkens11, James A Hutchinson12, Giovanna Lombardi13, J Alejandro Madrigal14, Natalia Marek-Trzonkowska15, Eva M Martinez-Caceres16, Maria Grazia Roncarolo17, Silvia Sanchez-Ramon18, Aurore Saudemont14, Birgit Sawitzki19.
Abstract
Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT," which identifies hurdles hindering Treg clinical applications in Europe and provides possible solutions.Entities:
Mesh：
Year: 2015 PMID： 26355029 DOI： 10.1126/scitranslmed.aaa7721
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956